A major 23-year study on prostate cancer screening reveals that while more cases are detected, the actual reduction in death ...

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 ...

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part because researchers lack reliable ways to recreate the conditions cancer ...

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in ...

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part because researchers lack reliable ways to recreate the conditions cancer ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

In the United States, the Shield MCD test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) based on its strong performance in predicting the presence of ...

After a routine blood test led to his diagnosis, the 70-year-old travel expert urges everyone to prioritize health exams.

Urinary Tract Infections (UTIs) are one of the most common bacterial infections which can occur in people of any age. The epidemiological study shows that UTI cases increased by approximately 66 per ...

Nairobi is currently the epicenter of Kenya's cancer crisis, accounting for 13 percent of all reported cases nationwide. As ...

Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s ...

Detailed price information for Profound Medical Corp (PRN-T) from The Globe and Mail including charting and trades.